Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00433836 · ClinicalTrials.gov registry record · Phase 3

Effect of Valsartan Compared to Enalapril on Sitting Systolic Blood Pressure in Children With High Blood Pressure

A Phase 3 study, sponsored by Novartis Pharmaceuticals.

Completed
Registry status
Phase 3
Development phase
300
Enrollment target

NCT00433836: Completed Phase 3 study, sponsored by Novartis Pharmaceuticals.

NCT00433836 is a Phase 3 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 300 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (61% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00433836, a Phase 3 study, has completed, sponsored by Novartis Pharmaceuticals.

COMPLETED
Registry status
Phase 3
Development phase
300 participants
Enrollment target

Study Summary

The purpose of this 12-week active controlled trial is to evaluate the safety and efficacy of valsartan 80/160/320 mg (weight stratified) compared with enalapril 10/20/40 mg (weight stratified) on sitting systolic blood pressure (SSBP) in 6 - 17 year old children with hypertension (SSBP ≥ 95th percentile for age gender and height).

Primary Outcome

Mean sitting systolic blood pressure (MSSBP) change after 12 weeks of treatment measured by office blood pressure measurement.

Interventions

  • DRUG Valsartan
  • DRUG Enalapril

Trial Details

FieldValue
Enrollment Target 300 participants
Start Date 2007-01
Est. Completion 2009-02
Phase Phase 3
Novartis Pharmaceuticals

1,375 total trials

What the finished NCT00433836 record still lists

NCT00433836 is an interventional study that assigns participants to a tested intervention. The registered 300 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (61% lower).

The record links to 0 conditions, and to 2 interventions - of which Valsartan is the first listed.

NCT00433836 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00433836 about?

NCT00433836 is a clinical study titled "Effect of Valsartan Compared to Enalapril on Sitting Systolic Blood Pressure in Children With High Blood Pressure". The purpose of this 12-week active controlled trial is to evaluate the safety and efficacy of valsartan 80/160/320 mg (weight stratified) compared with enalapril 10/20/40 mg (weight stratified) on sitting systolic blood pressure (SSBP) in 6 - 17 year old children with hypertension (SSBP ≥ 95th perce...

What is the current status of trial NCT00433836?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 300 participants. The study started on 2007-01. Estimated completion is 2009-02.

What interventions are being tested in trial NCT00433836?

The interventions under investigation include: Valsartan (DRUG), Enalapril (DRUG).

Who is sponsoring clinical trial NCT00433836?

This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00433836's enrollment target sits among peer trials

300 1122nd of 2000 higher than 840 of 2,000 other Phase 3 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00353483 · 300 participants

    Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells

  • NCT00588185 · 300 participants · NA

    [18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer

  • NCT00682032 · 300 participants · NA

    The Effect of Beta-glucan in Non-Small Cell Lung Cancer

  • NCT00870064 · 300 participants · NA

    The Treatment of Type I Open Fractures in Pediatrics

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00433836, the US trial registry maintained by the National Library of Medicine. NCT00433836 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.